NAT1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1815994	0.68	12/20
SCHEMBL1250382	0.68	8/20
SCHEMBL1250384	0.68	8/20
SCHEMBL1812224	1.00	7/20
SCHEMBL1449166	0.74	7/20
SCHEMBL1249067	1.00	6/20
SCHEMBL1249069	1.00	6/20
SCHEMBL623589	0.56	6/20
SCHEMBL623590	0.56	6/20
SCHEMBL623591	0.56	6/20
SCHEMBL1247509	1.00	5/20
SCHEMBL1247510	1.00	5/20
SCHEMBL1125089	0.73	5/20
SCHEMBL1125091	0.73	5/20
SCHEMBL194557	0.66	5/20
SCHEMBL194558	0.66	5/20
SCHEMBL346693	0.66	5/20
SCHEMBL346694	0.66	5/20
SCHEMBL1249935	0.66	5/20
SCHEMBL1250567	0.66	5/20

Clinical trials — most relevant to NAT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis	PHASE4	RECRUITING
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD	PHASE4	RECRUITING
NAT2 in Re-challenge of INH in Patients With Hepatitis	PHASE4	UNKNOWN
Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis	PHASE2/PHASE3	COMPLETED
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Pharmacogenetics-guided Isoniazid Dosing in TB-HIV	PHASE2	UNKNOWN
Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension	PHASE2	NOT_YET_RECRUITING
A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide	PHASE2	RECRUITING
Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100	PHASE2	COMPLETED
Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine	PHASE1	COMPLETED
Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration	PHASE1	COMPLETED
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention	PHASE1	COMPLETED
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer	PHASE1	COMPLETED
A Study to Evaluate the Drug-drug Interaction and Safety Between BR6001-1 and BR6001-2	PHASE1	COMPLETED
Pharmacogenetics Study in Taiwan's Ethnic Groups	nan	COMPLETED
Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis	nan	UNKNOWN
Melatonin in Pregnancy	nan	COMPLETED
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
APAP Hepatotoxicity After Therapeutic Doses	nan	UNKNOWN
Pharmacogenetic Determinants Of Treatment Response In Children	nan	RECRUITING
Histamine Pharmacogenetics in Children With Atopic Dermatitis	nan	COMPLETED
Genetic and Clinical Characterization of Type 1 and 2 Narcolepsy in Adult and Pediatric Black and North African Populations	nan	NOT_YET_RECRUITING
Elucidating the Molecular and Biochemical Basis of the Human AhR-mutation Disease	nan	UNKNOWN
DNA Analysis of Blood and Tissue from Patients with Lung Cancer	nan	RECRUITING
Thermogenic Silencer Regulatory Factors in Humans	nan	ACTIVE_NOT_RECRUITING
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel	nan	COMPLETED
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC	nan	COMPLETED
Effect of Genetic Differences on Levels of Water Disinfection Byproducts in Blood After Showering	nan	COMPLETED
SHMT1 Polymorphism in Parkinson's Disease,	nan	UNKNOWN
Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NAT1 binder may also engage these)

Protein	Name	Similarity
P50295	—	1.000	P50295 →
P50293	—	1.000	P50293 →
P11246	—	1.000	P11246 →
P50297	—	1.000	P50297 →
Q1JPA6	—	1.000	Q1JPA6 →
P13914	—	1.000	P13914 →
P11245	—	1.000	P11245 →
Q7YRG5	—	1.000	Q7YRG5 →
P50294	—	1.000	P50294 →
P12275	—	1.000	P12275 →
P13913	—	1.000	P13913 →
P50298	—	1.000	P50298 →
P50296	—	1.000	P50296 →
O62696	—	0.999	O62696 →
P18605	—	0.997	P18605 →
P50292	—	0.996	P50292 →
B7SP66	—	0.986	B7SP66 →
K3VCL0	—	0.986	K3VCL0 →
W7NDP8	—	0.985	W7NDP8 →
B4NBB0	—	0.983	B4NBB0 →
Q5ZJM3	—	0.981	Q5ZJM3 →
Q2QEI3	—	0.981	Q2QEI3 →
Q9UUE3	—	0.980	Q9UUE3 →
Q33DX5	—	0.980	Q33DX5 →
Q5A931	—	0.980	Q5A931 →
P40506	—	0.980	P40506 →
Q67X99	—	0.980	Q67X99 →
Q54IU8	—	0.980	Q54IU8 →
Q6C3P4	—	0.980	Q6C3P4 →
Q8VYX1	—	0.980	Q8VYX1 →